Phase IIa randomized, double-blind, and placebo-controlled multicenter split body trial to determine safety, tolerability, and efficacy of repeated doses of ACOU085 for the prevention of hearing loss in testicular cancer patients receiving cisplatin

ACOU085 Study: Phase IIa trial on prevention of cisplatin-induced hearing loss in testicular cancer patients

Comprehensive Cancer Center Mainfranken

Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)

Weitere

Phase II

Herr PD Dr. Till  Meyer

Herr Prof. Dr. Kristen Rak

Frau PD Dr. Anna Katharina Seitz

Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Hals-Chirurgie

Universitätsklinikum Würzburg

Advanced

Therapeutisch